Kevin Dennis Green Sells 23,147 Shares of Cerus Co. (NASDAQ:CERS) Stock

Cerus Co. (NASDAQ:CERS - Get Free Report) CFO Kevin Dennis Green sold 23,147 shares of the firm's stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $1.45, for a total value of $33,563.15. Following the transaction, the chief financial officer now owns 912,607 shares in the company, valued at $1,323,280.15. This represents a 2.47 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Kevin Dennis Green also recently made the following trade(s):

• On Friday, March 7th, Kevin Dennis Green sold 31,148 shares of Cerus stock. The stock was sold at an average price of $1.50, for a total value of $46,722.00.
• On Monday, March 3rd, Kevin Dennis Green sold 60,656 shares of Cerus stock. The stock was sold at an average price of $1.58, for a total value of $95,836.48.

Cerus Price Performance

Shares of CERS traded up $0.01 during mid-day trading on Friday, hitting $1.54. The company's stock had a trading volume of 667,783 shares, compared to its average volume of 1,226,499. The company has a current ratio of 2.59, a quick ratio of 1.92 and a debt-to-equity ratio of 1.19. The firm has a 50-day simple moving average of $1.71 and a 200 day simple moving average of $1.75. The firm has a market capitalization of $285.19 million, a P/E ratio of -14.02 and a beta of 1.56. Cerus Co. has a 1-year low of $1.38 and a 1-year high of $2.54.

Remove Ads

Cerus (NASDAQ:CERS - Get Free Report) last posted its quarterly earnings results on Thursday, February 20th. The biotechnology company reported ($0.01) EPS for the quarter, meeting the consensus estimate of ($0.01). The business had revenue of $50.81 million during the quarter, compared to analysts' expectations of $50.81 million. Cerus had a negative return on equity of 40.55% and a negative net margin of 11.60%. Analysts predict that Cerus Co. will post -0.08 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Cantor Fitzgerald reaffirmed an "overweight" rating and set a $4.00 price objective on shares of Cerus in a research report on Friday, February 21st.

Hedge Funds Weigh In On Cerus

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Wealth Enhancement Advisory Services LLC acquired a new position in Cerus during the fourth quarter worth $25,000. Squarepoint Ops LLC increased its position in Cerus by 2,084.7% during the fourth quarter. Squarepoint Ops LLC now owns 492,732 shares of the biotechnology company's stock worth $759,000 after buying an additional 470,178 shares in the last quarter. Two Sigma Advisers LP increased its position in Cerus by 249.5% during the fourth quarter. Two Sigma Advisers LP now owns 254,100 shares of the biotechnology company's stock worth $391,000 after buying an additional 181,400 shares in the last quarter. Two Sigma Investments LP increased its position in Cerus by 121.6% during the fourth quarter. Two Sigma Investments LP now owns 595,234 shares of the biotechnology company's stock worth $917,000 after buying an additional 326,605 shares in the last quarter. Finally, State of Wyoming increased its position in Cerus by 39.1% during the fourth quarter. State of Wyoming now owns 129,840 shares of the biotechnology company's stock worth $200,000 after buying an additional 36,488 shares in the last quarter. 78.37% of the stock is owned by institutional investors and hedge funds.

About Cerus

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.